Myriad Genetics, VA to Assess Genetic Test for Major Depressive Disorder

Myriad Genetics, through its Assurex Health subsidiary, said today it will partner with the U.S. Department of Veterans Affairs to assess the company's GeneSight ® genetic test in veterans diagnosed with major depressive disorder (MDD).GeneSight will be evaluated in the PRIME Care (PRecision Medicine In MEntal Health Care) study, a randomized clinical trial designed to show the effectiveness of providing veterans suffering from depression, and their providers, the results of pharmacogenomic